0A8I Stock Overview
A clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Genprex, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.13 |
| 52 Week High | US$13.00 |
| 52 Week Low | US$0.30 |
| Beta | -1.29 |
| 11 Month Change | -56.42% |
| 3 Month Change | 57.06% |
| 1 Year Change | -87.61% |
| 33 Year Change | -98.16% |
| 5 Year Change | n/a |
| Change since IPO | -99.29% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0A8I | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -2.5% | 1.5% | 1.7% |
| 1Y | -87.6% | -16.3% | 8.4% |
Return vs Industry: 0A8I underperformed the UK Biotechs industry which returned -16.3% over the past year.
Return vs Market: 0A8I underperformed the UK Market which returned 8.4% over the past year.
Price Volatility
| 0A8I volatility | |
|---|---|
| 0A8I Average Weekly Movement | 114.6% |
| Biotechs Industry Average Movement | 9.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0A8I's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0A8I's weekly volatility has increased from 72% to 115% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 21 | Ryan Confer | www.genprex.com |
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company’s technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form.
Genprex, Inc. Fundamentals Summary
| 0A8I fundamental statistics | |
|---|---|
| Market cap | US$4.03m |
| Earnings (TTM) | -US$22.71m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.2x
P/E RatioIs 0A8I overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0A8I income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$22.71m |
| Earnings | -US$22.71m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.31 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 0A8I perform over the long term?
See historical performance and comparison